CHMP grants positive opinion for Clovis Oncology's Rubraca® (rucaparib) tablets
Clovis Oncology announced the EU’s CHMP has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated, high-grade epithelial ovarian, cancer. March 23, 2018